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Key Points:  
 
• Observational studies are necessary to evaluate rare or long-term drug effects that cannot be 
assessed in clinical trials 
• Models need to be specified correctly to avoid confounding and allocation bias 30 
• Including ever-vs-never exposure to drugs together with cumulative exposure helps control 
these issues 
• We demonstrate this using statin exposure on Cardiovascular disease, as statin effects on 
CVD are well known 
• We also provide a mathematical explanation of how modelling cumulative and ever-35 
exposure jointly controls for time-invariant allocation bias 
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Abstract 
 
Purpose: To demonstrate a modelling approach that controls for time-invariant allocation bias in 
estimation of associations of outcome with drug exposure.   
Methods: We show that in a model that includes terms for both ever- versus never-exposure and 5 
cumulative exposure, the parameter for ever-exposure represents the effect of time-invariant 
allocation bias and the parameter for cumulative exposure represents the effect of the drug after 
adjustment for this unmeasured confounding. This assumes no stepwise effect of the drug on the 
event rate, no reverse causation, and no unmeasured time-varying confounders. We demonstrated 
this by modelling the effect of statins on cardiovascular disease, for which the true effect has been 10 
well-characterized in randomized trials, using time-updated Cox regression models in a national 
cohort of Type 2 diabetes patients.    
Results: The crude hazard ratio associated with ever-use of statins was 1.13 in a standard cohort 
analysis comparing exposed with unexposed person-time intervals. When ever-never use and 
cumulative exposure are modelled jointly, the effect of statins can be estimated from the cumulative 15 
exposure parameter (hazard ratio 0.97 per year of exposure, 95% CI 0.97 to 0.98). The ever-
exposed term (hazard ratio 1.20, 1.16 to 1.23) in this model can be interpreted as estimating the 
allocation bias. 
Conclusions: Where stepwise effects on the risk of adverse events are unlikely, as for instance for 
effects on risk of cancer, joint modelling of ever-never and cumulative exposure can be used to 20 
study the effects of multiple drugs and to distinguish causal effects from confounding by allocation. 
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Introduction 
Clinical trials are usually not of sufficient size or duration to capture all clinically important adverse 
or unexpected beneficial effects of drugs. Thus observational pharmaco-epidemiological studies 
remain important as a means of evaluating drug safety.1,2 Such observational studies have a range of 
design and interpretation challenges one of the most important being termed confounding by 5 
indication or ‘allocation bias’. Such confounding can occur when simple comparisons of rates of 
outcomes are made between those exposed (hereafter ever-users) and those not exposed to a drug 
(hereafter never-users) at some point in time. In these comparisons, ever-users and never-users of 
the drug may differ in susceptibility to the outcome in question for reasons independent of the drug. 
In other words, propensity to be prescribed the drug is associated positively or negatively with the 10 
outcome in question. Such confounding by indication or allocation bias cannot reliably be dealt 
with by simple adjustment for measured covariates such as past medical history because there are 
subtle unmeasured confounders such as co-morbidity that are not fully captured by the information 
in medical records.3 Propensity score matching, which matches exposed and unexposed individuals 
on covariates that predict drug allocation, does not overcome this limitation of relying on measured 15 
covariates.4 One approach to dealing with such fixed between-person confounding by indication or 
allocation bias that can be useful for assessing certain drugs and outcomes of interest is to focus 
inference about drug effects on whether the outcome changes with cumulative exposure - a well-
known concept in epidemiology that is enshrined in the dose-response criterion of Bradford Hill's 
criteria for causality 5 - and to contrast person-time-intervals with high cumulative exposure with 20 
person-time intervals with low (but nonzero) cumulative exposure.  
 
Investigators have used various approaches to modelling cumulative exposure effects of drugs. 
Typically models use categorical terms for cumulative exposure with the reference category being 
intervals or persons in which no exposure has occurred. We and others 6 have used models where 25 
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time updated terms for ever versus never exposure and cumulative exposure are included 
simultaneously in the model. This has the advantage of permitting evaluation of cumulative 
exposure whilst allowing simultaneous evaluation of cumulative effects of other drugs and use of all 
covariate data. We have used this approach to show for example that thiazolidinediones are 
associated with increased risk of hip fracture 7, and that there was no detectable effect of 5 
pioglitazone with bladder cancer.8   
 
In this paper we explore further the characteristics of such cumulative effects models, what 
allocation related biases they help overcome and which sorts of allocation-related bias they do not 
avoid. To do this, we use data on statin exposure and cardiovascular disease to illustrate the 10 
different estimates that are obtained when simple models of ever versus never exposure are used 
compared with models of cumulative exposure since the effects on cardiovascular disease (CVD) 
have been demonstrated unequivocally in randomized trials 9–12 and since it is expected that there 
will be a difference in the prior risk of CVD in those prescribed versus not prescribed statins. We 
emphasise of course that studies of association of drug exposure with outcomes are not sufficient to 15 
prove causality but are useful along with other considerations of causality in assessing effects of 
drugs in observational studies. Since they are commonly used,13–19 our exploration of such 
modelling is of practical relevance to interpreting observational pharmaco-epidemiological studies. 
 
Methods 20 
Data source 
We used data from a previously described diabetes register in Scotland (SCI-Diabetes) that captures 
all issued prescriptions (but not prescription encashments) for any diagnosis and other covariate 
data on the total population with diabetes since 2004.20 These data were linked using the national 
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unique health care identifier, the Community Health Index number, to the national hospital 
admissions dataset and to the national death register which extend back to 1981. 
Inclusion criteria, entry and exit times 
All those aged at least 18 years when diagnosed with type 2 diabetes and in the register at any point 
between 01/01/2004 (study start date) and 31/12/2011 (study end date) were included. Those with a 5 
CVD event prior to entry date, as identified from the hospital admissions database (see definition 
below), were excluded. The entry date into this study depends on diabetes diagnosis date: if the 
patient was diagnosed prior to study start date, they entered the study when they first became 
observable for drugs (an individual was considered to be observable for drugs when they received at 
least one prescription of any kind in a six month period) on or after study start date. If they were 10 
diagnosed after study start date, they entered the study when they first become observable for drugs 
on, or after their diabetes diagnosis date. All such persons are fully observable for national hospital 
admissions and deaths. The exit date for each person was the earliest of: first CVD event, death, 
study end date, or ceasing to be evaluable for prescribing and admission data i.e. exit from the 
country. Individuals who were already taking a statin at the time they first came under observation 15 
for drugs were excluded because their cumulative exposure was unknown. Any individual 
contributing less than 28 days to the study was excluded. In total we included 982,571 person-years 
at risk with 626,667 accruing for ever-exposed and 355,904 for never-exposed. 
Events 
CVD events were defined as hospital admission or death with any of the following ICD9 codes 20 
(410-414, 431, or 433-435) or ICD10 codes (I20–I25, I61, I63, I64, or G45). During the study there 
were 32,201 events, 8,573 (26.6%) among never-users and 23,628 (73.4%) in ever-users. 
Data preparation for modelling and calculation of exposure 
The period of follow-up was divided into discrete intervals of equal length to allow time-updating 
of covariates.21 For initial analyses, a 56-day interval length was used. Shortening this to 28-day 25 
Page 6 of 19 
intervals changed the effect estimates only slightly in the third significant digit: this 28-day interval 
was therefore taken to be sufficiently close to the theoretical limit of a model with infinitesimally 
short time intervals. A data matrix was generated with one row for each person-time interval during 
which the individual was under observation, and columns specifying event status at end and drug 
exposure and covariate values at the beginning of each 28 day interval. Cumulative exposure in 5 
days at the start of each interval was calculated as a sum over all earlier intervals in which a statin 
prescription was current. The exposure duration was calculated as the sum of drug eras, where each 
drug era is a sequence of prescriptions where the issue date does not exceed 56 days from the end of 
the previous prescription. This cut-off for defining drug eras has been validated (for other drugs) by 
using the directions for use (dosage and frequency) and the total quantity dispensed to calculate the 10 
durations of prescriptions. Gaps between drug eras were not included in exposure time. Following 
drug cessation the cumulative exposure was carried forward in subsequent time intervals. 
Covariates were sex, time-updated age at beginning of interval, age at diabetes diagnosis, calendar 
time, smoking (ever/never), low density lipoprotein (LDL) cholesterol, systolic blood pressure, 
diastolic blood pressure, glycosylated haemoglobin A1c (HbA1c), estimated glomerular filtration rate 15 
(eGFR), body mass index, ever-exposure to statins (defined to take values 1, 0 according to whether 
the person has ever been exposed to statin before or during that person-time interval) and 
cumulative exposure to statins (defined as cumulative years of statin use). The ever-exposed and 
cumulative exposure variables are not collinear as long as at least one individual is exposed for at 
least two 28-day intervals. 20 
Statistical methods 
Cox regression models for time to failure were specified to include statin exposure as (i) only the 
time-updated ever-never exposure term (ii) both the ever-never term and a linear term for 
cumulative exposure and (iii) cumulative exposure coded as a categorical variable, with baseline 
category defined as either (a) unexposed person-time intervals or (b) exposure greater than zero but 25 
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less than 0.5 years. A mathematical explanation of how modelling cumulative exposure and ever-
exposure jointly controls for time-invariant allocation bias is given in the online supplementary 
material. 
 
Results 5 
To show how the association of statin exposure with CVD is confounded, Table 1 compares CVD 
risk factor status in ever-users compared to never-users as of study mid-point (July 1st 2007). 
Levels of most CVD risk factors were higher in ever-users than in never-users. Table 2 shows the 
results of fitting Cox proportional hazards models in which statin exposure is coded as time-updated 
ever-use, comparing models with and without an additional term for cumulative exposure. With 10 
statin exposure coded only as ever-use, as in a standard cohort analysis of a time-varying exposure, 
statin exposure is associated with a higher event rate. Adjusting for additional covariates - smoking 
status, body mass index, total cholesterol, HbA1c, eGFR, systolic and diastolic blood pressure, and 
use of anti-hypertensive drugs - reduces the size of the hazard ratio parameter from 1.13 to 1.05, but 
does not reverse its direction. If naively interpreted, this would suggest an effect of statin use on 15 
CVD opposite in direction to that demonstrated by many clinical trials.22 This illustrates that 
adjusting for the risk factors that are typically available in an electronic health record is not enough 
to control for confounding by indication or allocation bias. 
 
Adding a linear term for cumulative exposure to statins to this model increases the hazard ratio 20 
associated with ever-use of statins from 1.13 to 1.20, but shows an inverse relationship of 
cardiovascular risk to cumulative exposure that is consistent in direction with the protective effect 
that has been demonstrated in trials. Adjustment for additional covariates changed the hazard ratio 
for cumulative exposure only slightly from 0.97 to 0.96 per year of exposure. 
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The form of the relationship of cardiovascular risk to cumulative exposure to statins is examined 
further in Table 3, which summarizes two alternative models in which cumulative exposure is 
coded as a categorical variable. In columns two to five, the model encodes cumulative exposure 
with unexposed person-time intervals as the baseline category, corresponding to a standard analysis 5 
of a cohort study to evaluate cumulative exposure.23,24 With this model, those exposed to statins 
appear to have increased risk for CVD initially, which is inconsistent with the trial evidence that the 
risk of CVD begins falling from the start of statin usage. In columns six to nine of Table 3, 
unexposed person-time intervals are excluded and the baseline category for cumulative exposure is 
the first exposed category (up to 6 months). With this model, the direction of the cumulative effect 10 
is consistent with trial evidence. The same hazard ratios can be generated from a dataset that 
includes unexposed person time-intervals if this model includes a time-updated term for ever-
exposure and up to 6 months (including unexposed person-time intervals) as the baseline category 
for cumulative exposure.   
 15 
To make this clear without resorting to statistical modelling, Figure 1 shows the age-standardised 
rates for CVD by cumulative statin exposure. The highest rates are for those in the initial period of 
exposure to statins, followed by a decline. This is consistent with allocation of higher-risk 
individuals to statin, and a protective effect of the drug. 
 20 
Discussion 
In pharmacoepidemiology, confounders of the association between drug exposure and outcome 
include subtle factors influencing drug allocation that are not recorded in electronic health records. 
We have demonstrated that evaluating statin effects simply by comparing rates in exposed and 
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unexposed person-time intervals would lead to erroneous conclusions about statin effects on CVD, 
as the rate of cardiovascular events is higher in exposed than in unexposed person-time intervals. 
This is to be expected, as current guidelines for statin prescribing emphasize that they are indicated 
in patients at high risk of cardiovascular disease. Even where additional efforts are made to collect 
data on and adjust for confounders, for instance in studies of the benefits and risks associated with 5 
post-menopausal oestrogen replacement therapy,25 it is still difficult to eliminate the allocation bias 
that results from unmeasured confounding. By contrasting person-time intervals with high and low 
cumulative exposure among those who have been prescribed the drug at least once, we can 
eliminate time-invariant confounding by factors associated with allocation (i.e. fixed allocation 
bias). 10 
 
One might ask why one cannot simply evaluate drug effects by comparing the rate of the event of 
interest in users prior to the start (of drug use) with their rate as their use accumulates. The reason is 
that for many exposures and outcomes of interest it is necessary to restrict the study to incident first 
events because the event itself may alter the probability of subsequent exposure. One might also ask 15 
why one cannot just measure the rate directly at the time of initiation of the drug and then assess 
whether it subsequently changes. The reason is that unfeasibly large sample sizes would be needed 
to give a reliable estimate of the ratio of the rate in this short time interval at the start of exposure to 
the unexposed rate. Instead the rate at the time of initiation of exposure is estimated by 
extrapolating back to zero the line (or curve) fitted for the relation of risk to years of cumulative 20 
exposure. The ratio of this estimated rate to the rate in unexposed person time intervals corresponds 
to the parameter for ever-exposure. If the time course of the effect of the drug on the hazard rate has 
been modelled correctly (as a line or curve), this parameter for ever-exposure represents the 
allocation bias. This is an example of the more general principle that the crude rate ratio can be 
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factored into a parameter that measures the strength of confounding and an adjusted parameter that 
measures the effect of exposure.26 
 
A simpler approach is to limit all analyses to exposed person-time intervals, and to estimate 
cumulative effects among these exposed individuals. However, such an approach does not fully use 5 
all the information on effects of other covariates on the outcome that may be available in the full 
dataset. These effects include calendar time effects which may be closely correlated with 
cumulative exposure. Most importantly, the exposed-only approach can be used only to study one 
drug at a time, and cannot be used to model the joint effects of several drugs. 
 10 
For the regression coefficients for ever-never and cumulative exposure to be interpreted as 
parameters that measure respectively the strength of confounding and the causal effect of the 
exposure, several assumptions are required. First, it is assumed that there is no stepwise effect of the 
drug on the event rate, so that the event rate in individuals who have just started the drug can be 
estimated by extrapolating the relationship (not necessarily linear) of hazard rate to cumulative 15 
exposure back to zero. This is a reasonable assumption for example when the adverse event under 
study is cancer (since tumours take many years to grow), or osteoporotic fractures (though an 
increase in fracture risk could result from a stepwise effect on falls rather than a cumulative effect 
on bone density. For cardiovascular disease, the plausibility of assuming no stepwise effect depends 
upon whether the drug effects are on the underlying atherosclerosis, which develops and regresses 20 
only slowly, or on more immediate triggers such as plaque rupture and thrombosis. For evaluating 
drug effects such as acute liver toxicity that might be expected to occur quickly after exposure, a 
cumulative exposure term would be hard to interpret. Second, it is assumed that the allocation bias 
is time-invariant. For instance, if higher-risk patients are more likely than lower risk patients to 
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discontinue the drug in the first few months because of adverse effects, estimation of the cumulative 
exposure term would falsely indicate a protective effect. Third it is assumed that there is no reverse 
causation, as for instance where a disease process causes a drug to be prescribed before the 
underlying disease is diagnosed. In this situation, incidence of the disease will be high shortly after 
the time of initiation of the drug and will fall with increasing cumulative exposure. An example of 5 
this is the association between exposure to insulin and pancreatic cancer.27 
 
Large scale observational pharmaco-epidemiological studies are becoming increasingly feasible as 
large electronic databases of drug exposures and health outcomes become available. Several 
scientists have written elegantly about the perils of such studies and the ease which errors in design 10 
can be made (26–30). For example, Suissa has emphasised that incorrect design and analytic 
methods in such studies frequently gives rise to immortal-time bias, which can be viewed as a 
differential misclassification of exposure status in relation to time to event.28–30 Unfortunately the 
analyses in many published studies in this field are still affected by some form of confounding or 
bias, limiting the conclusions that can be drawn despite the wealth of data available (27–29). Van 15 
Staa et al demonstrated the issues relating to allocation bias in their study of diabetes treatment and 
cancer risk.31 Thus, improving the methodology for analysing these data is vital. In this paper we 
aimed to provide some useful insights to those considering modelling cumulative effects as one of 
the possible means to reduce the potential for allocation bias. We emphasise that associations 
between drug exposures and outcomes are only one element to consider in assessing the evidence 20 
for causality. Consideration must be given to other factors including consistency of effects in 
different settings and biological plausibility. 
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Table 1. Description of Study Population on July 1st 2007 (Study Mid-Point) by Ever-Never Statin Use.  
 Statin user (N=90417) † Non-statin (N=30254) † p-value Missing (%) 
Age (years) 66.3 (57.4, 73.4) 65.4 (54.4, 75.4) <0.001 0 (0) 
Male (%) 45618 (50.5) 16442 (54.3) <0.001 0 (0) 
Ever smoker (%) 61694 (68.2) 19074 (63.0) <0.001 0 (0) 
Diabetes duration (years) 5.4 (2.7, 9.5) 4.4 (1.3, 8.6) <0.001 0 (0) 
Age at diagnosis (years) 58.6 (50.0, 67.0) 59 (48.2, 69.0) <0.001 0 (0) 
BMI (kg/m2) 30.6 (27.1, 34.9) 30.1 (26.3, 34.9) <0.001 8457 (7.1) 
Systolic blood pressure (mmHg) 135.0 (126.0, 142.0) 136.0 (126.0, 144.0) <0.001 2535 (2.1) 
Diastolic blood pressure (mmHg) 77.0 (70.0, 81.0) 78.0 (70.0, 82.0) <0.001 2535 (2.1) 
Total cholesterol (mmol/L) 4.1 (3.6, 4.7) 4.5 (4.0, 5.1) <0.001 4136 (3.4) 
HbA1c (mmol/L) ‡ 54.1 (47.5, 65.0) 54.1 (46.4, 65.0) 0.075 3254 (2.7) 
On anti-hypertensive drug (%) 68232 (75.5) 16381 (54.1) <0.001 0 (0) 
Estimated glomerular filtration rate (ml/min/1.73m2) 66.8 (55.1, 79.2) 68.5 (56.5, 81.6) <0.001 10728 (8.89) 
† Median (IQR) unless otherwise indicated;  ‡ HbA1c – glycosylated haemoglobin A1c 
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Table 2. Hazard Ratios for Incident CVD Using a Time-Updated Ever-Never Exposure Term Only. 
 Model with ever-exposure term only Model with terms for ever-exposure and cumulative 
exposure 
 
Hazard Ratio 
Lower 
95% 
Confidenc
e bound 
Upper 
95% 
Confidenc
e bound p-value 
Hazard 
Ratio 
Lower 
95% 
Confidenc
e bound 
Upper 
95% 
Confidenc
e bound p-value 
Current age (years) † 1.04 1.04 1.05 <0.001 1.05 1.04 1.06 <0.001 
Gender (female vs male) 0.79 0.77 0.80 <0.001 0.79 0.77 0.80 <0.001 
Age at diabetes diagnosis 
(years) 
0.98 0.97 0.98 <0.001 0.97 0.97 0.98 <0.001 
Statins ever vs never 
exposure 
1.13 1.10 1.16 <0.001 1.20 1.16 1.23 <0.001 
Cumulative statin 
exposure (years) 
- - - - 0.97 0.97 0.98 <0.001 
† Models included linear and quadratic terms for age 
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Table 3. Hazard ratios for incident CVD in models with cumulative statin exposure coded as discrete categories, illustrating effect of choice of 
baseline category. Models include sex, age at baseline, age at diabetes diagnosis, and time-updated calendar time.   
 
With baseline category as  unexposed person-time 
intervals 
With baseline category as exposed person-time intervals 
with cumulative exposure < 0.5 years 
Years of cumulative 
exposure Hazard Ratio 
Lower 95% 
Confidence 
bound 
Upper 95% 
Confidence 
bound p-value Hazard Ratio 
Lower 95% 
Confidence 
bound 
Upper 95% 
Confidence 
bound p-value 
   0 < exposure <=0.5 1.29 1.24 1.34 <0.000 NA NA NA NA 
0.5< exposure <=1.5 1.13 1.09 1.17 <0.000 0.88 0.84 0.92 <0.001 
1.5< exposure <=2.5 1.07 1.03 1.12 0.001 0.83 0.79 0.87 <0.001 
2.5< exposure <=3.5 1.09 1.04 1.14 <0.000 0.85 0.81 0.89 <0.001 
3.5< exposure <=4.5 1.09 1.04 1.14 0.001 0.84 0.80 0.89 <0.001 
4.5< exposure <= 5.5 1.06 1.01 1.12 0.023 0.83 0.78 0.88 <0.001 
5.5< exposure <=6.5 1.04 0.98 1.11 0.186 0.81 0.76 0.86 <0.001 
6.5< exposure <=7.5 1.05 0.98 1.13 0.157 0.82 0.76 0.88 <0.001 
7.5< exposure <=8.5 1.07 0.95 1.20 0.245 0.83 0.74 0.94 0.002 
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Figure legend: Age-standardised rates of CVD by cumulative exposure to statins. The error bars 
indicate the 95% CI for the rates. The x axis shows cumulative years of exposure; the data point 
at x = 0 is for all unexposed person time-periods, and the other data points are for exposure 
categories 0 < x ≤ 0.5, 0.5 < x ≤ 1, 1 < x ≤ 1.5, 1.5 < x ≤ 2, 2 < x ≤ 2.5, 2.5 < x ≤ 3, 3 < x ≤ 3.5,  
3.5 < x ≤ 4, 4 < x ≤ 4.5, 4.5 < x ≤ 5, 5 < x ≤ 5.5, 5.5 < x ≤ 6, and 6 < x ≤ 6.5. The rates in the initial 5 
exposed time period will reflect the starting rate and any effect of the drug within that time interval. 
To estimate the rate at the point of exposure a fitted line or curve through the points representing 
exposed person-time intervals would have to be extrapolated back to zero exposure i.e. the intercept 
on the Y-axis. The ratio of the observed rate in unexposed intervals and the fitted rate at the point of 
starting exposure in those exposed is the effect of confounding by indication or allocation bias. 10 
Where the time course effect is correctly modelled this is given by the hazard ratio for the ever 
never term in the model described.  
 
